التفاصيل البيبلوغرافية
| العنوان: |
REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes. |
| المؤلفون: |
Aleppo, Grazia, Ruedy, Katrina J., Riddlesworth, Tonya D., Kruger, Davida F., Peters, Anne L., Hirsch, Irl, Bergenstal, Richard M., Toschi, Elena, Ahmann, Andrew J., Shah, Viral N., Rickels, Michael R., Bode, Bruce W., Philis-Tsimikas, Athena, Pop-Busui, Rodica, Rodriguez, Henry, Eyth, Emily, Bhargava, Anuj, Kollman, Craig, Beck, Roy W., REPLACE-BG Study Group |
| المصدر: |
Diabetes Care; Apr2017, Vol. 40 Issue 4, p538-545, 8p, 4 Charts |
| مصطلحات موضوعية: |
BLOOD sugar monitoring, TYPE 1 diabetes, INSULIN pumps, HYPOGLYCEMIA, DISEASES in adults, PATIENTS, BLOOD sugar analysis, COMPARATIVE studies, GLYCOSYLATED hemoglobin, RESEARCH methodology, MEDICAL cooperation, RESEARCH, RESEARCH funding, STATISTICAL sampling, SOCIOECONOMIC factors, EVALUATION research, RANDOMIZED controlled trials |
| مستخلص: |
Objective: To determine whether the use of continuous glucose monitoring (CGM) without confirmatory blood glucose monitoring (BGM) measurements is as safe and effective as using CGM adjunctive to BGM in adults with well-controlled type 1 diabetes (T1D).Research Design and Methods: A randomized noninferiority clinical trial was conducted at 14 sites in the T1D Exchange Clinic Network. Participants were ≥18 years of age (mean 44 ± 14 years), had T1D for ≥1 year (mean duration 24 ± 12 years), used an insulin pump, and had an HbA1c ≤9.0% (≤75 mmol/mL) (mean 7.0 ± 0.7% [53 ± 7.7 mmol/mol]); prestudy, 47% were CGM users. Participants were randomly assigned 2:1 to the CGM-only (n = 149) or CGM+BGM (n = 77) group. The primary outcome was time in range (70-180 mg/dL) over the 26-week trial, with a prespecified noninferiority limit of 7.5%.Results: CGM use averaged 6.7 ± 0.5 and 6.8 ± 0.4 days/week in the CGM-only and CGM+BGM groups, respectively, over the 26-week trial. BGM tests per day (including the two required daily for CGM calibration) averaged 2.8 ± 0.9 and 5.4 ± 1.4 in the two groups, respectively (P < 0.001). Mean time in 70-180 mg/dL was 63 ± 13% at both baseline and 26 weeks in the CGM-only group and 65 ± 13% and 65 ± 11% in the CGM+BGM group (adjusted difference 0%; one-sided 95% CI -2%). No severe hypoglycemic events occurred in the CGM-only group, and one occurred in the CGM+BGM group.Conclusions: Use of CGM without regular use of confirmatory BGM is as safe and effective as using CGM with BGM in adults with well-controlled T1D at low risk for severe hypoglycemia. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetes Care is the property of American Diabetes Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder